Envista is a medical instruments & supplies business based in the US. Envista shares (NVST) are listed on the NYSE and all prices are listed in US Dollars. Envista employs 12,700 staff and has a trailing 12-month revenue of around $2.6 billion.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $31.89 |
|---|---|
| 52-week range | $31.67 - $43.94 |
| 50-day moving average | $37.07 |
| 200-day moving average | $36.28 |
| Wall St. target price | $44.50 |
| PE ratio | 28.681 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.16 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $31.89 from 2023-05-31
| 1 week (2023-05-25) | -3.22% |
|---|---|
| 1 month (2023-05-01) | -16.97% |
| 3 months (2023-03-01) | -17.40% |
| 6 months (2022-12-01) | -9.40% |
| 1 year (2022-06-01) | -24.09% |
|---|---|
| 2 years (2021-06-01) | -25.70% |
| 3 years (2020-06-01) | 48.67% |
| 5 years (2018-05-28) | N/A |
Valuing Envista stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Envista's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $2.6 billion |
|---|---|
| Operating margin TTM | 13.48% |
| Gross profit TTM | $1.5 billion |
| Return on assets TTM | 3.29% |
| Return on equity TTM | 5.09% |
| Profit margin | 8.27% |
| Book value | $26.14 |
| Market capitalisation | $5.4 billion |
TTM: trailing 12 months
We're not expecting Envista to pay a dividend over the next 12 months.
Over the last 12 months, Envista's shares have ranged in value from as little as $31.67 up to $43.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Envista's is 1.4216. This would suggest that Envista's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant for treatment planning of dental implants; DTX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic, a software package offered with its imaging devices. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals.
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.